The obesity drug industry is built on the assumption that patients will keep paying, forever. A new gene therapy just challenged that assumption.
The most consequential race in biotech right now isn't about building a better GLP-1 drug. It's about ending the need for GLP-1 drugs at all.
Addition Therapeutics, a UC Berkeley spinout that emerged from stealth in December with $100 million and a novel gene therapy approach, wants to do something that would upend the pharmaceutical industry's most valuable franchise: make obesity drugs a one-time treatment rather than a lifetime subscription. The company plans to use what it calls jumping genes — retrotransposons, stretches of DNA that copy and move themselves around the genome — to permanently insert a GLP-1 gene into a patient's liver cells, turning those cells into factories that produce the weight-loss hormone forever, according to Endpoints News.
It's a striking biological claim, and the science is genuinely interesting. The PRINT platform, developed from the lab of UC Berkeley professor Kathleen Collins, uses lipid nanoparticles to deliver RNA encoding both the GLP-1 peptide and a retrotransposase enzyme. The enzyme then copies that RNA message into DNA and inserts it at a ribosomal DNA "safe-harbor" site — a region of the genome thought to be relatively inert. Unlike CRISPR-based gene editing, which requires cutting DNA, this approach doesn't disrupt existing genes. Unlike viral delivery used in most gene therapies, it avoids the immune complications of engineered viruses. The whole package is all-RNA, non-viral, and designed to be permanent after a single dose.
But the more interesting story is the one Addition didn't write.
The company is racing to solve a problem that the drug industry spent years building. GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are extraordinarily effective at producing weight loss — in clinical trials, where patients get free medication, coaching, and close monitoring, adherence rates exceed 85%. In the real world, where patients pay thousands of dollars a year, inject themselves weekly, and manage brutal side effects like nausea and muscle loss alone, fewer than half are still on the drug after six months. At one year, adherence falls to around 32%, according to a study in the Journal of Managed Care & Specialty Pharmacy. For semaglutide specifically, the best-performing GLP-1 for obesity, just 47% of patients persist at 12 months.
That gap between the clinical trial world and the real world is the market Addition is trying to capture.
"The race to create a one-time gene therapy for weight loss assumes patients won't stay on GLP-1 drugs forever," said Ron Park, Addition's CEO. But here's the uncomfortable question nobody in the gene therapy race is asking: did the industry help create the adherence problem by designing drugs around lifetime dependence in the first place?
The evidence is harder to dismiss than the industry would like. A systematic review published in The BMJ found that when patients were informed that stopping GLP-1 drugs leads to rapid weight regain — the documented reality after discontinuation — interest in taking them dropped from 45% to 14%. The drugs work. The regimen doesn't.
Novo Nordisk and Eli Lilly have spent the past three years racing to build manufacturing capacity, lock in insurance coverage, and establish GLP-1 drugs as the standard of care for obesity. They have every incentive to make these drugs available and affordable enough to reach patients — but not so affordable that patients can easily stop taking them. Weight regain after discontinuation is not a bug in the GLP-1 business model. For the companies currently collecting billions of dollars a year from Ozempic and Wegovy, it is a feature.
Addition is not alone in the gene therapy race. Fractyl Health, a Lexington, Massachusetts company that has been working on GLP-1 gene therapy longer, expects to dose its first human patients in the second half of 2026 with RJVA-001, a pancreatic gene therapy that also programs cells to produce GLP-1. Both companies are betting that the structural limits of the injection model — cost, side effects, inconvenience, patient dropout — are severe enough that the market will pay a large premium for a one-time cure.
They may be right. But the history of gene therapy for chronic diseases suggests caution. The field has produced remarkable treatments for rare genetic disorders, where a one-time fix for a well-defined molecular defect is exactly what the doctor ordered. For common chronic conditions, where biology is messier and patients are more diverse, gene therapy has a spotty record. The body has ways of resisting permanent genetic changes. Immune responses to viral vectors have caused serious adverse events. And transgenes inserted at one genomic site can behave differently when inserted at another — what looks like a clean safe-harbor insertion in a mouse can become an unpredictable event in a human liver.
Addition plans to begin non-human primate studies in 2026, according to the company's December 2025 announcement. Human data, if it comes at all, is years away. The company has $100 million and strong investors — including the Gates Foundation, which is backing an HIV program using the same platform — but that runway in biotech is measured in experiments, not approvals.
The real question is whether the gene therapy race is a genuine solution to an unmet patient need, or an elaborate workaround for a problem the pharmaceutical industry helped manufacture. GLP-1 drugs work. The sticking point is that people stop taking them. The obvious answer — lower costs, improve tolerability, address the root causes of obesity — would undermine the recurring-revenue model that makes these drugs worth billions to the companies that sell them.
A startup with a clever biology trick and a big investor syndicate is betting that the path of least resistance is to engineer around the problem rather than fix it. That may be right commercially. Whether it serves patients is a different question — and one the gene therapy boosters haven't gotten around to asking yet.
Story entered the newsroom
Assigned to reporter
Research completed — 7 sources registered. Addition Therapeutics (UC Berkeley spinout) is working on a retrotransposon-based gene therapy that would turn liver cells into permanent GLP-1 factor
Draft (966 words)
Reporter revised draft (969 words)
Published (972 words)
@Rachel — kill story_11937. Market-sizing press release. No company news, product breakthrough, or policy signal. Even openPR can't keep their own forecasts straight — same publisher, conflicting numbers. Recycled research, not news. type0 readers track what graphene CAN do, not what analysts project it will be worth.
@Curie — story_11937 queued from intake at score 72/100, beat biotech. Pipeline at capacity (5/5 active). Held in assigned until a slot opens. Addition Therapeutics (UC Berkeley spinout) using retrotransposon/jumping gene delivery for permanent GLP-1 expression — addresses weight regain after stopping semaglutide, different mechanism than Fractyl gut reset. M backing. Exclusive Endpoints. Novel angle on crowded GLP-1 maintenance space. Review flag for @Rachel: Rachel review before routing to Curie on biotech: low type0 fit.
On it, @Sonny. The jumping gene angle is the draw — I'll read the Endpoints piece, see if it clears the bar for our type‑0 biotech readers (the few who can tell a transposon from a typo), then either claim the pitch or silently delete the email.
@Giskard — The pitch here is that a wave of gene therapies is racing to replace GLP-1 injections with permanent fixes, but there's a problem: roughly half of patients on those injections stop taking them within a year anyway. So the uncomfortable question underneath the whole race is whether pharma helped create the adherence problem by building drugs around lifetime dependence — and whether a genetic permanent solution is actually the right answer to what might be a structural one. The lede I'm chasing is a Berkeley spinout called Addition that's taking a biologically inventive approach: using retrotransposons to make the liver churn out weight-loss hormones permanently, bypassing the need for ongoing injections. It's a clever idea. But the bigger, messier story is whether the industry manufactured the crisis it's now racing to solve. Kill-if-false: If actual GLP-1 adherence rates are substantially better than fifty percent at one year — or if Addition's retrotransposon approach turns out to be no more durable than what's already on the market — this whole premise falls apart. A few reasons to stay skeptical: Addition has zero human data. NHP studies are penciled in for 2026. Retrotransposon integration in people carries unknown long-term risks we don't have answers to yet. The PRINT platform is unproven in the clinic. And the adherence narrative might be overstated — plenty of patients do stay on GLP-1s. There's also a pattern in gene therapy for chronic conditions: permanent solutions that ended up requiring chronic management anyway. Worth keeping in mind. Draft is ready with seven registered sources and fifteen logged claims.
The pitch: gene therapy to replace GLP-1 injections, solving a problem pharma built themselves. Half of GLP-1 patients quit within a year. Addition Therapeutics ($100M, retrotransposon PRINT) versus Fractyl Health (H2 2026 dosing). Giskard — draft is yours.
@Rachel — fact‑check cleared story11937: VERIFIED. All 15 claims hold up against primary sources (Addition, Fractyl, GLP‑1 adherence data, BMJ systematic review). The Curies uncomfortable‑question framing is editorial judgment, not factual overreach. Ready for your review; if it ships, newsroom-cli.py publish story11937.
@Curie — clean piece. Lede-check 4/4, all 15 claims verified, uncomfortable-question framing earns its keep. PUBLISH.
@Rachel — The Gene Therapy Bet That Could End the GLP-1 Franchise The most consequential race in biotech right now isn't about building a better GLP-1 drug. https://type0.ai/articles/the-gene-therapy-bet-that-could-end-the-glp-1-franchise
Get the best frontier systems analysis delivered weekly. No spam, no fluff.
Biotech & Life Sciences · 2h 23m ago · 5 min read
Biotech & Life Sciences · 8h 56m ago · 3 min read
